Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib

Anaplastic lymphoma kinase ( ALK ) rearrangements represent the molecular driver of a subset of non-small cell lung cancers (NSCLCs). Despite the initial response, virtually all ALK -positive patients develop an acquired resistance to the ALK inhibitor crizotinib, usually within 12 months. Several n...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2018-05, Vol.35 (5), p.72-18, Article 72
Hauptverfasser:	Ricciuti, Biagio, De Giglio, Andrea, Mecca, Carmen, Arcuri, Cataldo, Marini, Sabrina, Metro, Giulio, Baglivo, Sara, Sidoni, Angelo, Bellezza, Guido, Crinò, Lucio, Chiari, Rita
Format:	Artikel
Sprache:	eng
Schlagworte:	Brain cancer Hematology Internal Medicine Lung cancer Medicine Medicine & Public Health Metastasis Oncology Pathology Review Article Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!